Development of a new treatment of urinary stone disease

Information

  • Research Project
  • 6485376
  • ApplicationId
    6485376
  • Core Project Number
    R41DK060251
  • Full Project Number
    1R41DK060251-01A1
  • Serial Number
    60251
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/4/2002 - 22 years ago
  • Project End Date
    8/31/2004 - 20 years ago
  • Program Officer Name
    NYBERG, LEROY M.
  • Budget Start Date
    9/4/2002 - 22 years ago
  • Budget End Date
    8/31/2004 - 20 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    9/2/2002 - 22 years ago
Organizations

Development of a new treatment of urinary stone disease

DESCRIPTION (provided by applicant): Development of a new method for prophylaxis and treatment of urinary stone disease is proposed. Since a majority of urinary stones are made of calcium oxalate, the level of urinary oxalate is one of the major risk factors of stone formation. Unfortunately, there is no effective pharmacological treatment of stone disease that targets urinary oxalate concentration. Our method is based on chemical trapping of carbonyl precursors of oxalate biosynthesis and, thus, decreasing urinary oxalate concentration. In the preliminary experiments we have effectively trapped oxalate precursors glycolaldehyde and glyoxylate in vitro, and have reduced urinary oxalate excretion in normal animals (rats). In the current Phase I application we propose to check whether our treatment will result in trapping of oxalate precursors and reduction of urinary oxalate levels in the rat model of hyperoxaluna. If these Phase I experiments demonstrate the feasibility of the proposed approach, in Phase Il we will conduct human studies and optimize our method for patient treatment. Proposed Commercial Applications: Given the frequency of urinary stone disease and high rates of recurrent stone formation, there is a significant market potential for the proposed pharmacological treatment.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R41
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    100000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:100000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOSTRATUM, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    DURHAM
  • Organization State
    NC
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    27703
  • Organization District
    UNITED STATES